Exhibits practically 10x benefit in general survival at 36 months primarily based on ctDNA standing and affirms Signatera’s potential to foretell chemotherapy profit
Exhibits a 50% discount in threat of loss of life for Signatera-positive sufferers when handled with ACT
AUSTIN, Texas–(BUSINESS WIRE)–Natera, Inc. (NASDAQ: NTRA), a worldwide chief in cell-free DNA and genetic testing, introduced that new information from the GALAXY arm of the continued CIRCULATE-Japan trial was launched at present on the 2024 Congress of the European Society for Medical Oncology (ESMO) in Barcelona, Spain. GALAXY is among the largest and most complete potential research of circulating tumor DNA (ctDNA) testing in resectable colorectal most cancers (CRC).
This newest evaluation, which may also be printed in Nature Drugs on September 16, supplies the primary proof of the power of Signatera-based molecular residual illness (MRD) detection to foretell general survival (OS). The information additionally demonstrates Signatera’s potential to foretell adjuvant chemotherapy (ACT) profit in resectable CRC, with ctDNA clearance as an indicator of a superior survival profit in comparison with no clearance.
Within the research, 2,240 sufferers with stage II“IV CRC had been monitored utilizing Signatera after curative-intent surgical procedure with a median follow-up of 23 months. Key takeaways embrace:
Signatera standing was predictive of general survival. Signatera-positivity within the post-op MRD window was discovered to be considerably related to worse OS in comparison with Signatera-negative sufferers (HR: 9.68, p-value‰Signatera standing was predictive of an general survival profit from adjuvant chemotherapy.Excessive-risk stage II and stage III-IV sufferers who had been Signatera-positive after surgical procedure and obtained ACT demonstrated superior OS (adjusted HR: 0.53, p-value = 0.05), similar to a 50% discount within the threat of loss of life when handled with ACT. By comparability, the MOSAIC trial1, which was the final practice-changing research in adjuvant CRC, demonstrated a 16% discount in threat of loss of life (HR: 0.84, p-value = 0.05).Signatera-negative sufferers didn’t derive an OS profit from ACT (adjusted HR: 0.53, p-value = 0.13).Signatera standing remained essentially the most vital predictor of recurrence. Signatera-positivity after surgical procedure was the only most important prognostic issue related to inferior DFS (HR 12.08, p-value Sustained Signatera clearance after ACT was related to improved survival. Sufferers who clear ctDNA and remained Signatera-negative (known as sustained clearance) had superior survival profit with 24-month OS of 100%. This compares to sufferers who cleared ctDNA for a time period however later change into Signatera-positive (known as transient clearance), with 24-month OS of 82%, and sufferers who didn’t obtain ctDNA clearance, with 24-month OS of 61%. This discovering additional helps the utility of sustained ctDNA clearance as a surrogate endpoint for long-term outcomes.
We now have compelling potential proof from a big trial of greater than 2,200 sufferers that clearly reinforces the hyperlink between MRD standing and general survival, stated Yoshiaki Nakamura, MD, PhD, co-author of the paper and principal investigator of the research from the Nationwide Most cancers Heart Hospital East in Kashiwa, Chiba, Japan. These findings counsel that Signatera can predict post-surgical outcomes for colorectal most cancers sufferers with nice precision, redefining the way forward for personalised medication and offering the potential to considerably enhance outcomes for a better variety of sufferers.
The GALAXY information launched at present builds on an earlier evaluation from the identical research that was printed in Nature Drugs in 2023, stated Minetta Liu, MD, chief medical officer of oncology at Natera (NASDAQ:). Introducing 36-month, first-of-its-kind information on general survival is a crucial milestone that reinforces the potential to enhance outcomes for sufferers identified with colorectal most cancers. The up to date information affirms ctDNA standing as a crucial measure each for prognosis and for predicting which sufferers could actually profit from adjuvant chemotherapy.
About Signatera
Signatera is a personalised, tumor-informed, molecular residual illness check for sufferers beforehand identified with most cancers. Customized-built for every particular person, Signatera makes use of circulating tumor DNA to detect and quantify most cancers left within the physique, establish recurrence sooner than commonplace of care instruments, and assist optimize remedy choices. The check is on the market for medical and analysis use and is roofed by Medicare for sufferers with colorectal most cancers, breast most cancers, ovarian most cancers and muscle invasive bladder most cancers, in addition to for immunotherapy monitoring of any stable tumor. Signatera has been clinically validated throughout a number of most cancers sorts and indications, with printed proof in additional than 70 peer-reviewed papers.
About Natera
Natera™ is a worldwide chief in cell-free DNA and genetic testing, devoted to oncology, girls’s well being, and organ well being. We goal to make personalised genetic testing and diagnostics a part of the usual of care to guard well being, and inform earlier, extra focused interventions that assist result in longer, more healthy lives. Natera’s exams are validated by greater than 200 peer-reviewed publications that reveal excessive accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories licensed underneath the Medical Laboratory Enchancment Amendments (CLIA) in Austin, Texas and San Carlos, California. For extra info, go to www.natera.com.
Ahead-Wanting Statements
All statements aside from statements of historic info contained on this press launch are forward-looking statements and usually are not a illustration that Natera’s plans, estimates, or expectations shall be achieved. These forward-looking statements symbolize Natera’s expectations as of the date of this press launch, and Natera disclaims any obligation to replace the forward-looking statements. These forward-looking statements are topic to identified and unknown dangers and uncertainties that will trigger precise outcomes to vary materially, together with with respect as to if the outcomes of medical or different research will assist using our product choices, the influence of outcomes of such research, our expectations of the reliability, accuracy and efficiency of our exams, or of the advantages of our exams and product choices to sufferers, suppliers and payers. Further dangers and uncertainties are mentioned in better element in “Threat Components” in Natera’s latest filings on Kinds 10-Okay and 10-Q and in different filings Natera makes with the SEC infrequently. These paperwork can be found at www.natera.com/buyers and www.sec.gov.
References
Thierry André et al., Improved General Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Therapy in Stage II or III Colon Most cancers within the MOSAIC Trial. JCO 27, 3109-3116(2009). DOI:10.1200/JCO.2008.20.6771
View supply model on businesswire.com: https://www.businesswire.com/information/house/20240914884883/en/
Investor Relations: Mike Brophy, CFO, Natera, Inc., 510-826-2350, investor@natera.comMedia: Lesley Bogdanow, VP of Company Communications, Natera, Inc., pr@natera.com
Supply: Natera, Inc.